A Single Dose (Part 1) and Multiple Dose (Part 2) Phase I, Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers
Latest Information Update: 19 Dec 2014
At a glance
- Drugs Urocanic acid (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Laurantis Pharma
- 19 Dec 2014 New trial record